Literature DB >> 19829072

Establishment and characterization of patient tumor-derived head and neck squamous cell carcinoma xenografts.

Mukund Seshadri1, Mihai Merzianu, Haikuo Tang, Nestor R Rigual, Maureen Sullivan, Thom R Loree, Saurin R Popat, Elizabeth A Repasky, Bonnie L Hylander.   

Abstract

The overall purpose of this study was to establish human head and neck squamous cell carcinoma (HNSCC) xenografts in mice by transplantation of surgical tumor tissue and to characterize the growth, histologic and vascular properties of these xenografts. Primary surgical specimens of HNSCC were xenografted into eight-to-twelve week old severe combined immunodeficiency (SCID) mice. Histologic features of primary HNSCC specimens, initial and established xenografts were compared for tumors established from three different head and neck subsites, namely, oral cavity, larynx and base of tongue (one tumor per site). Growth rates of xenografts were compared along with magnetic resonance imaging (MRI) measures of tumor vascularity and correlative CD31-immunostaining. Initial and established xenografts from all three sites demonstrated a squamous phenotype similar to the original patient tumor histology. Established xenografts of oral cavity and larynx exhibited increased keratinization (H&E) compared to initial xenografts and the primary tumor. No differences in tumor growth rates were observed between established xenografts from the different subsites. Xenografts established from SCC of the larynx exhibited increased microvessel density and lumen area (CD31 staining) along with enhanced permeability to the MR contrast agent compared to oral cavity and base of tongue tumors. Our results show that the combination of non-invasive imaging along with histologic evaluation of patient tumor xenografts offers a valuable platform for preclinical investigations in head and neck cancer. However, it is important to recognize the influence of tumor-host interactions on the histologic phenotype of transplanted tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19829072      PMCID: PMC2906774          DOI: 10.4161/cbt.8.23.10137

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  34 in total

1.  Treatment of advanced head and neck cancer: what lessons have we learned?

Authors:  Barbara A Conley
Journal:  J Clin Oncol       Date:  2006-03-01       Impact factor: 44.544

2.  Prognostic relevance of CD105+ microvessel density in HNSCC patient outcome.

Authors:  Tiziana Martone; Paola Rosso; Roberto Albera; Giuseppe Migliaretti; Flavio Fraire; Lorenzo Pignataro; Giancarlo Pruneri; Graziella Bellone; Giorgio Cortesina
Journal:  Oral Oncol       Date:  2005-02       Impact factor: 5.337

3.  Antitumor efficacy testing in rodents.

Authors:  Melinda G Hollingshead
Journal:  J Natl Cancer Inst       Date:  2008-10-28       Impact factor: 13.506

4.  Histopathological characteristics predictive for growth of squamous cell carcinomas of the head and neck heterotransplanted to nude mice.

Authors:  J Wennerberg; R Willén; A Biörklund; C Tropé
Journal:  Anticancer Res       Date:  1986 Sep-Oct       Impact factor: 2.480

5.  Preservation of morphological, functional, and karyotypic traits during long-term culture and in vivo passage of two human skin squamous cell carcinomas.

Authors:  W Tilgen; P Boukamp; D Breitkreutz; R T Dzarlieva; M Engstner; D Haag; N E Fusenig
Journal:  Cancer Res       Date:  1983-12       Impact factor: 12.701

6.  Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights.

Authors:  Karl Turetschek; Anda Preda; Viktor Novikov; Robert C Brasch; Hanns J Weinmann; Patrick Wunderbaldinger; Timothy P L Roberts
Journal:  J Magn Reson Imaging       Date:  2004-07       Impact factor: 4.813

Review 7.  Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions.

Authors:  Anwar R Padhani
Journal:  J Magn Reson Imaging       Date:  2002-10       Impact factor: 4.813

8.  Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas.

Authors:  Quynh-Thu Le; Christina Kong; Phillip W Lavori; Ken O'byrne; Janine T Erler; Xin Huang; Yijun Chen; Hongbin Cao; Robert Tibshirani; Nic Denko; Amato J Giaccia; Albert C Koong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-09-01       Impact factor: 7.038

9.  A new model of patient tumor-derived breast cancer xenografts for preclinical assays.

Authors:  Elisabetta Marangoni; Anne Vincent-Salomon; Nathalie Auger; Armelle Degeorges; Franck Assayag; Patricia de Cremoux; Ludmilla de Plater; Charlotte Guyader; Gonzague De Pinieux; Jean-Gabriel Judde; Magali Rebucci; Carine Tran-Perennou; Xavier Sastre-Garau; Brigitte Sigal-Zafrani; Olivier Delattre; Véronique Diéras; Marie-France Poupon
Journal:  Clin Cancer Res       Date:  2007-07-01       Impact factor: 12.531

10.  Size, shape, structure, and direction of angiogenesis in laryngeal tumour development.

Authors:  J Laitakari; V Näyhä; F Stenbäck
Journal:  J Clin Pathol       Date:  2004-04       Impact factor: 3.411

View more
  19 in total

1.  p27(Kip1) enforces maintenance of quiescence in the mammalian ear and the pituitary gland.

Authors:  Martine Roussel
Journal:  Cell Cycle       Date:  2011-08-15       Impact factor: 4.534

2.  Targeting mesenchymal exaptation to mitigate tumor growth.

Authors:  Sufi Mary Thomas; Jennifer Rubin Grandis
Journal:  Cell Cycle       Date:  2011-08-15       Impact factor: 4.534

3.  Impact of Short-term 1,25-Dihydroxyvitamin D3 on the Chemopreventive Efficacy of Erlotinib against Oral Cancer.

Authors:  Katelyn D Bothwell; Tatiana Shaurova; Mihai Merzianu; Amritha Suresh; Moni A Kuriakose; Candace S Johnson; Pamela A Hershberger; Mukund Seshadri
Journal:  Cancer Prev Res (Phila)       Date:  2015-06-22

4.  Proteomic Characterization of Head and Neck Cancer Patient-Derived Xenografts.

Authors:  Hua Li; Sarah Wheeler; Yongseok Park; Zhenlin Ju; Sufi M Thomas; Michele Fichera; Ann M Egloff; Vivian W Lui; Umamaheswar Duvvuri; Julie E Bauman; Gordon B Mills; Jennifer R Grandis
Journal:  Mol Cancer Res       Date:  2015-12-18       Impact factor: 5.852

5.  Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts.

Authors:  Shousong Cao; Farukh A Durrani; Karoly Toth; Youcef M Rustum; Mukund Seshadri
Journal:  Oral Oncol       Date:  2011-05-06       Impact factor: 5.337

6.  Monitoring antivascular therapy in head and neck cancer xenografts using contrast-enhanced MR and US imaging.

Authors:  Mukund Seshadri; Nuno T Sacadura; Tonya Coulthard
Journal:  Angiogenesis       Date:  2011-09-07       Impact factor: 9.596

7.  Vascular priming enhances chemotherapeutic efficacy against head and neck cancer.

Authors:  Margaret Folaron; James Kalmuk; Jaimee Lockwood; Costakis Frangou; Jordan Vokes; Steven G Turowski; Mihai Merzianu; Nestor R Rigual; Maureen Sullivan-Nasca; Moni A Kuriakose; Wesley L Hicks; Anurag K Singh; Mukund Seshadri
Journal:  Oral Oncol       Date:  2013-07-23       Impact factor: 5.337

8.  Influence of the implantation site on the sensitivity of patient pancreatic tumor xenografts to Apo2L/TRAIL therapy.

Authors:  Rohit Sharma; Sandra Buitrago; Rose Pitoniak; John F Gibbs; Leslie Curtin; Mukund Seshadri; Elizabeth A Repasky; Bonnie L Hylander
Journal:  Pancreas       Date:  2014-03       Impact factor: 3.327

9.  Combined magnetic resonance and optical imaging of head and neck tumor xenografts using Gadolinium-labelled phosphorescent polymeric nanomicelles.

Authors:  Rajiv Kumar; Tymish Y Ohulchanskyy; Steve G Turowski; Mark E Thompson; Mukund Seshadri; Paras N Prasad
Journal:  Head Neck Oncol       Date:  2010-11-26

10.  Origin of the vasculature supporting growth of primary patient tumor xenografts.

Authors:  Bonnie L Hylander; Natalie Punt; Haikuo Tang; Joanna Hillman; Mary Vaughan; Wiam Bshara; Rose Pitoniak; Elizabeth A Repasky
Journal:  J Transl Med       Date:  2013-05-03       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.